This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Trojano, M Articles by Livrea, P Search for Related Content PubMed PubMed Citation Articles by Trojano, M Articles by Livrea, P Social Bookmarking                   What's this?

Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rIFNß-1b treatment

Institute of Clinical Neurology, University of Bari, Policlinico, Piazza G. Cesare, 70124 Bari, Italy

C Avolio

Institute of Clinical Neurology, University of Bari, Policlinico, Piazza G. Cesare, 70124 Bari, Italy

M Ruggieri

Institute of Clinical Neurology, University of Bari, Policlinico, Piazza G. Cesare, 70124 Bari, Italy

G Defazio

Institute of Clinical Neurology, University of Bari, Policlinico, Piazza G. Cesare, 70124 Bari, Italy

F Giuliani

Institute of Clinical Neurology, University of Bari, Policlinico, Piazza G. Cesare, 70124 Bari, Italy

D Paolicelli

Institute of Clinical Neurology, University of Bari, Policlinico, Piazza G. Cesare, 70124 Bari, Italy

P Livrea

Institute of Clinical Neurology, University of Bari, Policlinico, Piazza G. Cesare, 70124 Bari, Italy

The validity of serum sICAM-1 levels to assess Multiple Sclerosis (MS) activity was evaluated in 49 untreated definite relapsing-remitting (RR) patients. sICAM-1 levels were significantly (P = 0.0009) higher in the `clinically active' group (No 22) than in the `clinically inactive' (No 27), whereas no different values were found between patients with Gd-enhancing lesions at MRI (Gd-positive) (No 32) and patients without such lesions (Gd-negative) (No 17) independently of their clinical activity. Among the `clinically active' MS, the Gd-positive (No 16) subgroup showed significant (P50.05) lower sICAM-1 levels when compared to the Gd-negative (No 6) subgroup, but higher (P = 0.009) than those of the `clinically inactive Gd-positive' (No 16) patients. The sICAM-1 levels did not differ between the two `clinically inactive' subgroups Gd-positive (No 16) and Gd-negative (No 11). Finally the clinically active Gd-negative (No 6) showed sICAM-1 levels higher (P = 0.002) than the clinically inactive Gd-negative (No 11). The specificity of high serum sICAM-1 levels (above M+2 s.d. of control values) to assess the disease activity in MS resulted higher (100%) using clinical than Gd-MRI activity (76%) as gold standard. The changes induced by 1 year recombinant Interferon-b-1b (rIFNb-1b) treatment on sICAM- 1 serum levels were also longitudinally investigated in 36 of the 49 RR MS. sICAM-1 levels at baseline significantly increased in the first 2 months (baseline vs 1st month P50.0001 and 1st vs 2nd month P=0.02), persisted at high levels without any significant change after 3 months, showed a temporary decrease at 6 months, then significantly increased again at 9 and 12 months. Fourteen patients experienced relapses, with a total of 20 relapses, during the whole treatment duration. The mean relapse/rate and the frequency of patients with Gd-positive MRI scans resulted significantly higher in the first semester compared to the second semester of treatment. This study adds further insights into the validity of serum sICAM-1 to assess disease activity in MS and on the immunomodulatory properties of rIFNß-1b.

Key Words: soluble ICAM-1 • Gadolinium-MRI • rIFNß-1b

Multiple Sclerosis, Vol. 4, No. 3, 183-187 (1998)
DOI: 10.1177/135245859800400318


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. I. Boullerne, J. J. Rodriguez, T. Touil, B. Brochet, S. Schmidt, N. D. Abrous, M. Le Moal, J. R. Pua, M. A. Jensen, W. Mayo, et al. Anti-S-Nitrosocysteine Antibodies Are a Predictive Marker for Demyelination in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis J. Neurosci., January 1, 2002; 22(1): 123 - 132. [Abstract] [Full Text] [PDF]

				M. Gironi, V. Martinelli, E. Brambilla, R. Furlan, A. E. Panerai, G. Comi, and P. Sacerdote {beta}-Endorphin Concentrations in Peripheral Blood Mononuclear Cells of Patients With Multiple Sclerosis: Effects of Treatment With Interferon Beta Arch Neurol, August 1, 2000; 57(8): 1178 - 1181. [Abstract] [Full Text] [PDF]

				N. D Richert, M. C. Zierak, C. N Bash, B. K Lewis, H. F McFarland, and J. A Frank MRI and clinical activity in MS patients after terminating treatment with interferon beta-l b Multiple Sclerosis, April 1, 2000; 6(2): 86 - 90. [Abstract] [PDF]

				I. Elovaara, M. Ukkonen, M. Leppakynnas, T. Lehtimaki, M. Luomala, J. Peltola, and P. Dastidar Adhesion Molecules in Multiple Sclerosis: Relation to Subtypes of Disease and Methylprednisolone Therapy Arch Neurol, April 1, 2000; 57(4): 546 - 551. [Abstract] [Full Text] [PDF]